TYRA - CIK 0001863127
The table below shows Tyra Biosciences, Inc.'s balance sheet by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q1 2026 | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $84.95M | $61.95M | $98.49M | $100.72M | $103.89M | $99.49M |
| Short-term investments | - | - | - | - | - | - |
| Receivables | - | - | - | - | - | - |
| Inventory | - | - | - | - | - | - |
| Total current assets |
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| $394.61M |
| $281.22M |
| $302.15M |
| $324.57M |
| $365.61M |
| $378.57M |
| Property, plant & equipment | $1.22M | $1.35M | $1.41M | $1.52M | $1.79M | $1.90M |
| Goodwill | - | - | - | - | - | - |
| Total assets | $412.04M | $301.85M | $321.50M | $343.48M | $380.59M | $392.46M |
| Accounts payable | $3.64M | $1.99M | $2.25M | $2.50M | $1.17M | $1.58M |
| Total current liabilities | $19.26M | $15.88M | $13.77M | $14.25M | $12.37M | $10.38M |
| Long-term debt | - | - | - | - | - | - |
| Total liabilities | $24.46M | $21.34M | $19.35M | $19.94M | $18.30M | $16.42M |
| Retained earnings | -$410.56M | -$337.42M | -$307.56M | -$279.46M | -$225.74M | -$201.72M |
| Total equity | $387.57M | $280.51M | $302.15M | $323.53M | $362.29M | $376.04M |